Skip to main content
. 2017 Feb 25;8(5):793–800. doi: 10.7150/jca.17766

Figure 4.

Figure 4

Subgroup survival analysis. In patients with DHS of 0-1, those who received asparaginase-based regimens have better PFS (A); this survival benefit of asparaginased-based regimens was diminished in patients with DHS of 2 (B).